康宁杰瑞制药-B(09966)：JSKN033一线治疗晚期宫颈癌的II期临床研究完成首例患者给药

智通财经网05-13

智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，SKN033(一种由抗人表皮生长因子受体2(“HER2”)双特异性抗体偶联药物(“ADC(s)”)与程序性死亡配体1(“PD-L1”)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床研究(研究编号：JSKN033-202)已完成首例患者给药。JSKN033具备多项显著的差异化...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2635221155?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-13 08:09","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2635221155","market":"sg","top_or_hot":-1,"title":"康宁杰瑞制药-B(09966)：JSKN033一线治疗晚期宫颈癌的II期临床研究完成首例患者给药","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，SKN033(一种由抗人表皮生长因子受体2(“HER2”)双特异性抗体偶联药物(“ADC(s)”)与程序性死亡配体1(“PD-L1”)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床研究(研究编号：JSKN033-202)已完成首例患者给药。JSKN033具备多项显著的差异化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1440966.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康宁杰瑞制药-B(09966)：JSKN033一线治疗晚期宫颈癌的II期临床研究完成首例患者给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康宁杰瑞制药-B(09966)：JSKN033一线治疗晚期宫颈癌的II期临床研究完成首例患者给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-13 08:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1440966.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，SKN033(一种由抗人表皮生长因子受体2(“HER2”)双特异性抗体偶联药物(“ADC(s)”)与程序性死亡配体1(“PD-L1”)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床研究(研究编号：JSKN033-202)已完成首例患者给药。JSKN033具备多项显著的差异化...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1440966.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1440966.html","article_id":"2635221155","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635221155","pubTimestamp":1778630957,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"在早期临床研究中，JSKN033单药在经治晚期宫颈癌患者中已展现出优异疗效和可控安全性，为其一线联合治疗奠定了坚实基础。JSKN033-202是一项开放、多中心、II期临床研究，旨在评估JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌患者的安全性、有效性及药代动力学╱药效学特征。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","09966":"康宁杰瑞制药-B","BK1574":"生物医药B类股"},"translate_title":"Alphamab-B (09966): Phase II clinical study of JSKN033 for the first-line treatment of advanced cervical cancer completed the first patient administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1.5},"content_text":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，SKN033(一种由抗人表皮生长因子受体2(“HER2”)双特异性抗体偶联药物(“ADC(s)”)与程序性死亡配体1(“PD-L1”)免疫检查点抑制剂组成的高浓度皮下注射复方制剂)联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌的一项II期临床研究(研究编号：JSKN033-202)已完成首例患者给药。JSKN033具备多项显著的差异化优势：“秒钟级”皮下注射极大提升了用药便捷性与依从性;较低的血液学毒性使其成为少数能够与卡铂联用的ADCs之一，为不同肾功能、耐受性及用药习惯的患者提供了更灵活、更安全的用药方案。JSKN033联合铂类及贝伐珠单抗，有望同时发挥HER2 ADC靶向杀伤、免疫激活、抗血管生成与化疗的多重协同抗肿瘤作用，延长疾病控制时间，改善患者生存获益。在早期临床研究中，JSKN033单药在经治晚期宫颈癌患者中已展现出优异疗效和可控安全性，为其一线联合治疗奠定了坚实基础。JSKN033-202是一项开放、多中心、II期临床研究，旨在评估JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌患者的安全性、有效性及药代动力学╱药效学特征。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。铂类药物的选择和是否联用贝伐珠单抗将由研究者根据患者的具体情况决定。该研究的启动有望为晚期宫颈癌患者带来高效、安全、便捷的一线治疗新选择。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635221155","isCrawlerRequest":true}